Guided Therapeutics (GT) will be showcasing the LightTouch cervical neoplasia detection system in anticipation of a 2010 international launch. GT intends to meet with medical device distributors with gynecological market expertise, as well as government purchasing officials, in order to better understand the cervical cancer market structure in the various countries.
The company is also looking to identify physicians who specialize in colposcopy and cervical disease management in the interest of establishing partnerships for multinational clinical studies involving the LightTouch.
In conjunction with its partner Konica Minolta Opto of Tokyo, GT will also be holding design and feature requirement discussions with international healthcare professionals for its LightTouch technology for detecting and monitoring Barrett's esophagus.
Mark Faupel, president and CEO of GT, said: "We believe the LightTouch will significantly improve the standard of care in the area of cervical pre-cancer detection in a wide range of market settings. Our experience in launching new non-invasive detection technology indicates an international product launch - while the technology is undergoing FDA premarket review - permits us to have an earlier, positive affect on woman's healthcare while increasing shareholder value."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index